Did Aldeyra Therapeutics, Inc. (ALDX) Mislead Investors? Levi & Korsinsky Investigates

Core Viewpoint - Aldeyra Therapeutics, Inc. is under investigation for potential violations of federal securities laws following the FDA's Complete Response Letter indicating insufficient efficacy of its drug reproxalap for dry eye disease [1][3]. Group 1: Company Developments - Throughout 2024 and 2025, Aldeyra made optimistic forward-looking statements regarding the development and regulatory prospects of reproxalap, emphasizing its importance in the company's pipeline and commercial potential [2]. - The FDA issued a Complete Response Letter on March 17, 2026, stating that reproxalap had not demonstrated sufficient efficacy, contradicting the company's previous positive public statements about the drug's clinical data [3]. Group 2: Investigation Details - Levi & Korsinsky is investigating whether Aldeyra failed to disclose material information regarding efficacy risks that could have impacted the forward-looking statements made to shareholders [3].